José Javier Sánchez

16.1k total citations · 1 hit paper
90 papers, 6.0k citations indexed

About

José Javier Sánchez is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, José Javier Sánchez has authored 90 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pulmonary and Respiratory Medicine, 42 papers in Oncology and 35 papers in Molecular Biology. Recurrent topics in José Javier Sánchez's work include Lung Cancer Treatments and Mutations (41 papers), Cancer Genomics and Diagnostics (20 papers) and Lung Cancer Research Studies (17 papers). José Javier Sánchez is often cited by papers focused on Lung Cancer Treatments and Mutations (41 papers), Cancer Genomics and Diagnostics (20 papers) and Lung Cancer Research Studies (17 papers). José Javier Sánchez collaborates with scholars based in Spain, United States and Italy. José Javier Sánchez's co-authors include Rafael Rosell, Miquel Tarón, Carlos Camps, Enriqueta Felip, José Miguel Sánchez, Vicente Alberola, J Maestre, Dolores Isla, Rafael Rosell and Kathleen D. Danenberg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

José Javier Sánchez

87 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

2002 551 citations Carlos Camps, Manuel Dómine et al. profile →

Peers

José Javier Sánchez

ONCOL

PRM

SURGE

Philip C. Mack United States

Miquel Tarón Spain

Rafael Rosell Spain

Junichi Soh Japan

Antonio Jimeno United States

Michael L. Cher United States

Fred R. Hirsch United States

Samuel E. DePrimo United States

Martin Filipits Austria

Daniele Generali Italy

Philip C. Mack United States

José Javier Sánchez

2.9k ×0.9

3.8k ×1.3

ONCOL

3.5k ×1.2

PRM

1.9k ×1.2

510 ×0.9

SURGE

Citations per year, relative to José Javier Sánchez José Javier Sánchez (= 1×) peers Philip C. Mack

Countries citing papers authored by José Javier Sánchez

Since Specialization

Citations

This map shows the geographic impact of José Javier Sánchez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Javier Sánchez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Javier Sánchez more than expected).

Fields of papers citing papers by José Javier Sánchez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José Javier Sánchez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Javier Sánchez. The network helps show where José Javier Sánchez may publish in the future.

Co-authorship network of co-authors of José Javier Sánchez

This figure shows the co-authorship network connecting the top 25 collaborators of José Javier Sánchez. A scholar is included among the top collaborators of José Javier Sánchez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José Javier Sánchez. José Javier Sánchez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blanco, Miren, et al.. (2023). Sustainable biobased epoxy thermosets with covalent dynamic imine bonds for green composite development. Polymer. 285. 126339–126339. 20 indexed citations

Karachaliou, Niki, Carlota Costa, Ana Giménez‐Capitán, et al.. (2013). BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations. Journal of Thoracic Oncology. 8(3). 295–300. 15 indexed citations

Sánchez, José Javier, et al.. (2012). Polymorphisms in HIF-1alpha affect presence of lymph node metastasis and can influence tumor size in squamous-cell carcinoma of the glottic larynx. Clinical & Translational Oncology. 15(5). 358–363. 17 indexed citations

Casado, E., Víctor Moreno, José Javier Sánchez, et al.. (2011). A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer. Clinical Cancer Research. 17(12). 4145–4154. 25 indexed citations

Sirera, Rafael, Roy M. Bremnes, Andrea Cabrera‐Pastor, et al.. (2011). Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(2). 286–290. 69 indexed citations

Moreno, Víctor, Paloma Cejas, Jaime Feliú Batlle, et al.. (2009). Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. International Journal of Colorectal Disease. 24(7). 741–748. 47 indexed citations

Skrzypski, Marcin, Ewa Jassem, Miquel Tarón, et al.. (2008). Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. Clinical Cancer Research. 14(15). 4794–4799. 84 indexed citations

Wei, Jia, Zhengyun Zou, Xiaoping Qian, et al.. (2008). ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. British Journal of Cancer. 98(8). 1398–1402. 58 indexed citations

Felip, Enriqueta, Rafael Rosell, Bartomeu Massutí, et al.. (2007). B2-01: The NATCH trial: chemotherapy toxicity and response on the neoadjuvant arm. Journal of Thoracic Oncology. 2(8). S336–S336. 1 indexed citations

10.

Molina, Ana Ramı́rez de, Jacinto Sarmentero, Cristóbal Belda-Iniesta, et al.. (2007). Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. The Lancet Oncology. 8(10). 889–897. 130 indexed citations

11.

Camps, Carlos, Rafael Sirera, Roy M. Bremnes, et al.. (2006). Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications. Lung Cancer. 52(3). 343–347. 22 indexed citations

12.

Felip, Enriqueta, Miquel Tarón, Rafael Rosell, et al.. (2005). Clinical Significance of Hypoxia-Inducible Factor–1α Messenger RNA Expression in Locally Advanced Non–Small-Cell Lung Cancer After Platinum Agent and Gemcitabine Chemotherapy Followed by Surgery. Clinical Lung Cancer. 6(5). 299–303. 5 indexed citations

13.

Rodríguez‐Pinilla, María, José Luis Rodríguez‐Peralto, Ricardo Hitt, et al.. (2005). β-Catenin, Nf-κB and FAS protein expression are independent events in head and neck cancer: study of their association with clinical parameters. Cancer Letters. 230(1). 141–148. 16 indexed citations

14.

Camps, Carlos, Rafael Sirera, Roy M. Bremnes, et al.. (2005). Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?. Lung Cancer. 50(3). 339–346. 42 indexed citations

15.

Isla, Dolores, Carme Sarries, Rafael Rosell, et al.. (2004). Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer. Annals of Oncology. 15(8). 1194–1203. 255 indexed citations

16.

Camps, Carlos, Bárbara Roig, José Javier Sánchez, et al.. (2003). Assessment of Nucleotide Excision Repair XPD Polymorphisms in the Peripheral Blood of Gemcitabine/Cisplatin–Treated Advanced Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer. 4(4). 237–241. 42 indexed citations

17.

Sánchez, José Miguel, Carmen Balañá, Albert Font, et al.. (2002). Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Lung Cancer. 38(3). 309–315. 11 indexed citations

18.

Rosell, R., Enriqueta Felip, J Maestre, et al.. (2001). The role of chemotherapy in early non-small-cell lung cancer management. Lung Cancer. 34. 63–74. 22 indexed citations

19.

Martín, Miguel, et al.. (1996). Acute and anticipatory emesis in breast cancer patients. Supportive Care in Cancer. 4(5). 370–377. 17 indexed citations

20.

Espinosa, Enrique, Jaime Feliú, P. Zamora, et al.. (1995). Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 12(1-2). 67–76. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact